Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Author(s):
Marianna Fontana
,
Added:
1 month ago
Video Series
Obesity Management and Cardiovascular Disease
Author(s):
Miao Gao
,
Tanjot Singh
,
Ramzi Ajjan
Added:
2 months ago
Review Article
Author(s):
Harriette Van Spall
,
Julie De Backer
Added:
9 months ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this…
View more
Clinical Clues in Cardiovascular Disease
Video Series
Author(s):
Miguel García-Villarino
,
Elias Delgado
,
Carmen Lambert
,
et al
Added:
2 months ago
Cardiovascular Disease and Type 2 Diabetes
Author(s):
Martin Berger
,
Nikolaus Marx
,
Katharina Marx-Schütt
Added:
1 year ago
Review Article
Author(s):
Yassir Javaid, Michel Burnier, Mariya Tokmakova ,et al
Start date:
Jun 25, 2025
Join an expert panel of internationally recognised cardiovascular specialists for a CME-accredited* webinar on the latest strategies in hypertension management for patients with cardiovascular disease. Chaired by Dr Yassir Javaid (Imperial College Healthcare NHS Trust, London, UK), with Prof Michel Burnier (University Hospital of Lausanne, Lausanne, CH) Prof Mariya Tokmakova (Medical University…
View more
Cardiac Diseases in Sudan
Author(s):
Eldisugi Hassan Mohammed Humida
,
Hussain Gadelkarim Ahmed
Added:
4 days ago
Review Article
Added:
3 months ago
Source:
Radcliffe CVRM
For patients with elevated lipoprotein(a) [Lp(a)] and established cardiovascular disease (CVD), weekly lipoprotein apheresis (LA) is the only approved treatment, but it represents a significant burden. The Lp(a)FRONTIERS APHERESIS trial investigated whether the investigational therapy pelacarsen could reduce the need for this invasive procedure.¹Mechanism of ActionPelacarsen is a hepatocyte…
View more
Preterm Birth and Maternal Cardiovascular Risk
Author(s):
Jorge Segovia-Reyes
,
Andrea Iboleon-Jimenez
,
María Jiménez-Salva
,
et al
Added:
1 month ago
Review Article